Discussion # GS03-06 and GS03-07 Do we have a biomarker for adjuvant CDK4/6 inhibitors?
Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer
Comentários
Postar um comentário